| Emicizumab prophylaxis in hemophilia A with inhibitors J Oldenburg, JN Mahlangu, B Kim, C Schmitt, MU Callaghan, G Young, ... New England Journal of Medicine 377 (9), 809-818, 2017 | 1075 | 2017 |
| Emicizumab prophylaxis in patients who have hemophilia A without inhibitors J Mahlangu, J Oldenburg, I Paz-Priel, C Negrier, M Niggli, ME Mancuso, ... New England Journal of Medicine 379 (9), 811-822, 2018 | 679 | 2018 |
| Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study SW Pipe, M Shima, M Lehle, A Shapiro, S Chebon, K Fukutake, NS Key, ... The Lancet Haematology 6 (6), e295-e305, 2019 | 357 | 2019 |
| A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors G Young, RI Liesner, T Chang, R Sidonio Jr, J Oldenburg, ... Blood, The Journal of the American Society of Hematology 134 (24), 2127-2138, 2019 | 333 | 2019 |
| The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes JP Frias, EJ Bastyr, L Vignati, MH Tschoep, C Schmitt, K Owen, ... Cell Metabolism 26 (2), 343-352. e2, 2017 | 284 | 2017 |
| Disease–drug–drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis C Schmitt, B Kuhn, X Zhang, AJ Kivitz, S Grange Clinical Pharmacology & Therapeutics 89 (5), 735-740, 2011 | 263 | 2011 |
| Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies MU Callaghan, C Negrier, I Paz-Priel, T Chang, S Chebon, M Lehle, ... Blood, The Journal of the American Society of Hematology 137 (16), 2231-2242, 2021 | 211 | 2021 |
| Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays JI Adamkewicz, DC Chen, I Paz-Priel Thrombosis and haemostasis 119 (07), 1084-1093, 2019 | 125 | 2019 |
| A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A K Yoneyama, C Schmitt, N Kotani, GG Levy, R Kasai, S Iida, M Shima, ... Clinical pharmacokinetics 57, 1123-1134, 2018 | 99 | 2018 |
| Laboratory monitoring in emicizumab-treated persons with hemophilia A J Müller, I Pekrul, B Pötzsch, B Berning, J Oldenburg, M Spannagl Thrombosis and Haemostasis 119 (09), 1384-1393, 2019 | 87 | 2019 |
| Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study C Schmitt, JI Adamkewicz, J Xu, C Petry, O Catalani, G Young, C Negrier, ... Thrombosis and haemostasis 121 (03), 351-360, 2021 | 77 | 2021 |
| HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in … G Young, RF Sidonio, R Liesner, J Oldenburg, T Chang, M Uguen, ... Blood 130, 85, 2017 | 69 | 2017 |
| Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies I Paz-Priel, T Chang, E Asikanius, S Chebon, T Emrich, E Fernandez, ... Blood 132, 633, 2018 | 68 | 2018 |
| Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG 7697 … C Schmitt, A Portron, S Jadidi, N Sarkar, R DiMarchi Diabetes, Obesity and Metabolism 19 (10), 1436-1445, 2017 | 67 | 2017 |
| Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia Α with inhibitors: results from the HAVEN 2 study G Young, R Liesner, RF Sidonio Jr, J Oldenburg, V Jimenez-Yuste, ... Blood 132, 632, 2018 | 64 | 2018 |
| Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers C Schmitt, M Riek, K Winters, M Schutz, S Grange Archives of drug information 2 (1), 8-16, 2009 | 60 | 2009 |
| Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab–preclinical and clinical studies D Kling, C Stucki, S Kronenberg, D Tuerck, E Rhéaume, JC Tardif, ... Thrombosis Research 131 (5), 401-410, 2013 | 54 | 2013 |
| First-in-man study with inclacumab, a human monoclonal antibody against P-selectin C Schmitt, M Abt, C Ciorciaro, D Kling, C Jamois, E Schick, C Solier, ... Journal of cardiovascular pharmacology 65 (6), 611-619, 2015 | 51 | 2015 |
| Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG 7697 after single … A Portron, S Jadidi, N Sarkar, R DiMarchi, C Schmitt Diabetes, Obesity and Metabolism 19 (10), 1446-1453, 2017 | 42 | 2017 |
| Disease-drug interaction studies of tocilizumab with cytochrome P450 substrates in vitro and in vivo X Zhang, C Schmitt, S Grange, K Terao, K Miya, A Kivitz, M Marino Clinical Pharmacology & Therapeutics 85, S59-S59, 2009 | 41 | 2009 |
